So the share structure was changed prior to the en
Post# of 36532
(Total Views: 368)
Posted On: 08/04/2019 6:50:03 AM
So the share structure was changed prior to the end of the GNBT fiscal year? I assumed based on the 7/12/19 PR about the completion being after the fiscal year, the OS count would not have changed until 8/1 or slightly later. At least for Medisource.
Re Medisource: "Under the terms of the deal, Generex will acquire 100% of the assets of Medisource including business operations, accounts receivable and inventory, contracts, and real estate, in an all-stock transaction, effective August 1, 2019, following the close of Generex’ fiscal year."
Pantheon's PR didn't mention the fiscal year time frame, at least not that I saw.
Re Pantheon: "MIRAMAR, Fla., July 11, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has completed the acquisition of Pantheon Medical – Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools. Under the terms of the deal, Generex will acquire all of the assets of Pantheon Medical including business operations, accounts receivable and inventory, contracts, real estate, and an FDA letter related to balanced plating system, on a debt free basis, in a non-cash transaction with Generex (GNBT) stock, plus additional cash and stock consideration upon achieving certain sales and profit goals."
The PR's were 2 days apart 7/11 and 7/12.
I am not being argumentative. I have no knowledge re: the mechanics of how these transactions work and how/when Broadridge and/or OTC Markets update there records.
Re Medisource: "Under the terms of the deal, Generex will acquire 100% of the assets of Medisource including business operations, accounts receivable and inventory, contracts, and real estate, in an all-stock transaction, effective August 1, 2019, following the close of Generex’ fiscal year."
Pantheon's PR didn't mention the fiscal year time frame, at least not that I saw.
Re Pantheon: "MIRAMAR, Fla., July 11, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has completed the acquisition of Pantheon Medical – Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools. Under the terms of the deal, Generex will acquire all of the assets of Pantheon Medical including business operations, accounts receivable and inventory, contracts, real estate, and an FDA letter related to balanced plating system, on a debt free basis, in a non-cash transaction with Generex (GNBT) stock, plus additional cash and stock consideration upon achieving certain sales and profit goals."
The PR's were 2 days apart 7/11 and 7/12.
I am not being argumentative. I have no knowledge re: the mechanics of how these transactions work and how/when Broadridge and/or OTC Markets update there records.
(0)
(0)